News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Jenapharm's Therapeutics Business Sold To Dermapharm AG



10/19/2005 5:11:07 PM

BERLIN, August 12 /PRNewswire-FirstCall/ -- Schering AG (FSE: SCH, NYSE: SHR) announced today that its German subsidiary Jenapharm GmbH & Co. KG, Jena, has agreed the sale of its therapeutics business to mibe Vertriebsgesellschaft mbH (i.G.), Jena, a subsidiary of Dermapharm AG, Grunwald.

The sale of Jenapharm GmbH & Co. KG's largely generic therapeutics business is part of the Schering Group's strategic focus program. The transaction, whereby more than 80 Jenapharm employees will be taken on by mibe Vertriebsgesellschaft mbH (i.G.), Jena, should be completed by October 1, 2004. Jenapharm's therapeutics business generated net sales of EUR 38 million in 2003. Financial details of the transaction were not disclosed.

Additional information

Jenapharm's therapeutics business includes systemic corticoids, inhalative anti-asthmathics and medicines for treating osteoporosis and further indications. Products included are, for example, Prednisolut(R), Hydrocortison(R), Calcilac(R), Prednisolon(R) and Aescusan(R). The complete product range comprises approximately 65 products.

Schering AG is a research-based pharmaceutical company. Its activities are focused on four business areas: Gynecology&Andrology, Oncology, Diagnostic Imaging as well as Specialized Therapeutics for disabling diseases. As a global player with innovative products Schering AG aims for leading positions in specialized markets worldwide. With in-house R&D and supported by an excellent global network of external partners, Schering AG is securing a promising product pipeline. Using new ideas, Schering AG aims to make a recognized contribution to medical progress and strives to improve the quality of life: making medicine work

This press release has been published by Corporate Communication of Schering AG, Berlin, Germany.

Your contacts at Corporate Communication:

Media Relations: Oliver Renner, T: +49-30-468-124-31, oliver.renner@schering.de

Investor Relations: Niels Matusch, T: +49-30-468150-62, niels.matusch@schering.de

Find additional information at: www.schering.de/eng

Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and Schering AG's plans and objectives to differ materially from those expressed or implied in the forward-looking statements. Certain factors that may cause such differences are discussed in our Form 20-F and Form 6-K reports filed with the U.S. Securities and Exchange Commission. Schering AG undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.

Schering AG

CONTACT: Your contacts at Corporate Communication: Media Relations:Oliver Renner, T: +49-30-468-124 31, oliver.renner@schering.de;Investor Relations: Niels Matusch, T: +49-30-468150-62,niels.matusch@schering.de


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES